

**Zoledronic Acid Every 12 weeks.**

<b>Indication</b>	For treatment of patients with advanced malignancies involving the bone (excluding prostate cancer unless used as part of a pain management programme)
<b>Treatment Intent</b>	N/A
<b>Frequency and number of cycles</b>	Every 12 weeks for one year (possible extension to 2 years)
<b>Monitoring parameters pre-treatment</b>	<ul style="list-style-type: none"> <li>• C + G should be used to estimate CrCl prior to start of treatment and if creatinine rises during treatment</li> <li>• Monitor serum creatinine at each cycle. If renal function deteriorates d/w consultant</li> <li>• If CrCl 30-60 ml/min dose should be reduced, see SPC</li> <li>• Not recommended in patients with CrCl &lt;30 ml/min.</li> <li>• Monitor corrected calcium, phosphate and magnesium at each cycle</li> <li>• Adcal D3 to be dispensed every other cycle (cycles 1, 3, 5 etc)</li> <li>• In <u>multiple myeloma</u> patients, the risk of renal dysfunction may be increased when used in combination with thalidomide</li> </ul> <p><u>Osteonecrosis of the jaw</u></p> <ul style="list-style-type: none"> <li>• A dental examination with appropriate preventative dentistry should be considered prior to treatment</li> <li>• While on treatment avoid dental procedures if possible</li> </ul> <p><u>Osteonecrosis of the external auditory canal</u></p> <ul style="list-style-type: none"> <li>• May occur very rarely</li> </ul>
<b>Reference(s)</b>	SpC accessed online 22/01/2018 Hortobagyi GN et. al JAMA Oncol. 2017 Jul 1;3(7):906-912 JHimelstein AL et. al JAMA. 2017 Jan 3;317(1):48-58

**NB:** For funding information, refer to the SACT funding spreadsheet

**Every 12 weeks**

Day	Drug	Dose	Route	Infusion Duration	Administration Details
<b>1</b>	<b>ZOLEDRONIC ACID</b>	<b>4 mg</b>	<b>IV</b>	<b>15 minutes</b>	<b>In 100ml Sodium Chloride 0.9%</b>
TTOs	Drug	Dose	Route	<b>Directions</b>	
	<b>Calcium 600mg + colecalciferol 10 micrograms tablets (Adcal D3)</b>	<b>ONE Tablet</b>	<b>PO</b>	<b>Once daily, chewed or sucked before swallowing. Dispense 168 tablets every other cycle</b>	

Protocol No	SUPP-005	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.		
Version	1.0	Written by		C Waters
Supersedes version	n/a	Checked by		K Miller
Date	8/3/18	Authorising consultant (usually NOG Chair)		C Thomas